Mount Sinai Logo

Ajai Chari

  • ASSOCIATE PROFESSOR Medicine, Hematology and Medical Oncology
Print ProfilePrint Profile

Certifications

  • Hematology

  • Medical Oncology

Clinical Focus

  • AL Amyloidosis
  • Amyloidosis
  • Bone Marrow Transplantation
  • Bone Marrow Transplantation, Autologous
  • Clinical Trials
  • Hematologic Malignancies
  • Multiple Myeloma
  • Plasma Cell Neoplasms
  • Waldenström's Macroglobulinemia

Education

  • MD, UCLA School of Medicine

  • Residency, Internal Medicine
    Columbia University Medical Center

  • Fellowship, Hematology & Onc.
    University of California - San Francisco

Biography

    Dr Chari is an Associate Professor of Medicine, the Director of Clinical Research in the Multiple Myeloma Program, and the Associate Director of Clinical Research, Mt Sinai Cancer Clinical Trials Office. Clinical Interests: Plasma cell disorders, including multiple myeloma, AL amyloidosis, POEMS syndrome, plasmacytoma, and monoclonal gammopathies of uncertain significance (MGUS). Dr Chari has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. Research Interests: Dr Chari’s research interests include the development of novel chemotherapy regimens, including phase 1 and 2 studies. He is principal investigator (PI) of several investigator-initiated trials as well as the national and international PI of several industry sponsored studies. As the Director of Clinical Research in the Multiple Myeloma Program, he oversees a program renowned nationally not only for high volume patient accruals but also rigorous quality assurance. The program has played a pivotal role in the approval of each of the 5 most recent drugs to be approved by the FDA for the treatment of multiple myeloma.

Awards

  • -
    Best Junior Faculty Teacher Award, selected by 2008 Internal Medicine residency class, Columbia University College of Physicians and Surgeons

  • -
    New York Metro Super Doctors 2011-2015

  • 2013 -
    Health Care Provider of the Year, Leukemia Lymphoma Society

  • 2008 -
    Ewig Teaching Award, Deparatment of Medicine, Columbia University College of Physicians and Surgeons

  • 1994 -
    Phi Beta Kappa, Stanford University

Publications

Chari A, Mazumder A, Jagannath S. Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics : targets & therapy 2010; 4.

Barley K, Harris JA, Diefenbach C, Jagannath S, Chari A. Misdiagnosis of non-hodgkin lymphoma as multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Dec; 30(35).

Chari A, Barley K, Jagannath S, Osman K. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis. Clinical lymphoma, myeloma & leukemia 2013 Feb; 13(1).

Biran N, Jagannath S, Chari A. Risk stratification in multiple myeloma, part 1: characterization of high-risk disease. Clinical advances in hematology & oncology : H&O 2013 Aug; 11(8).

Biran N, Jagannath S, Chari A. Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies. Clinical advances in hematology & oncology : H&O 2013; 11(9).

Biran N, Ely S, Chari A. Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques. Current hematologic malignancy reports 2014 Dec; 9(4).

Chari A. Novel Targets in Multiple Myeloma. American Journal of Hematology/Oncology 2015 March ; 11(3): 11-16.

Clinical Trials

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Chari during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

  • Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Limited ); Novartis

Scientific Advisory Board:

  • Array BioPharma; Celgene Corporation; Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Limited ); Novartis; Onyx Pharmaceuticals, Inc.

Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.

  • Celgene Corporation

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.

Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.

Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central

Address

One Gustave L. Levy Place, Box 1185
New York, NY 10029

Ruttenberg Treatment Center

1470 Madison Avenue
3rd floor
New York, NY 10029

Tel: 212-241-6756
Fax: 212-241-8608
Get Directions
Insurance Plans
  • 1199
  • Access Meicare
  • Aetna
  • Affinity
  • Amerigroup
  • Cigna
  • Empire Blue Cross/Blue Shield
  • Fidelis
  • GHI
  • Health Insurance Plan (HIP)
  • Island Group
  • Magnacare
  • Medicaid of New York
  • Medicare
  • MetroPlus Health Plan
  • MultiPlan, Inc.
  • Oxford Health Plans
  • POMCO
  • United Healthcare
  • VNS Medicare
  • WellCare of New York, Inc.
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Discover
  • Personal Check
  • Cash